Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770990 | 0.93 | HSD11B1 (0.47) | HSD11B1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL770601 | 0.85 | EPHX2 (0.47) | HSD11B1EPHX2L3MBTL1NPC1ALDH1A1 | |
| SCHEMBL769928 | 0.85 | L3MBTL1 (0.46) | HSD11B1EPHX2L3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL771381 | 0.81 | GBA1 (0.47) | EPHX2NPC1RAB9AALDH1A1 | |
| SCHEMBL786891 | 0.79 | NPC1 (0.51) | HSD11B1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL772280 | 0.79 | NPC1 (0.48) | EPHX2NPC1RAB9ASMN1; SMN2DPP4 | |
| SCHEMBL770531 | 0.78 | L3MBTL1 (0.44) | HSD11B1EPHX2L3MBTL1NPC1ALDH1A1 | |
| SCHEMBL17690740 | 0.78 | SMN1; SMN2 (0.41) | HSD11B1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL770194 | 0.76 | EPHX2 (0.49) | EPHX2L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL771962 | 0.75 | NPC1 (0.49) | HSD11B1EPHX2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 1149/4885L3MBTL1 4097/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 1153/4885L3MBTL1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.